These two companies could move in different directions over the medium term.

Recursion Pharmaceuticals RXRX, a TechBio company, is expected to beat expectations when it reports third-quarter 2026 ...

One thing that stands out about Recursion right away is how the company refers to itself. Recursion doesn't say that it's a pharmaceutical, biopharmaceutical, or biotech company. Instead, it uses the ...

In the latest trading session, Recursion Pharmaceuticals (RXRX) closed at $4.03, marking a -4.95% move from the previous day. The stock's change was less than the S&P 500's daily loss of 1.82%.

Key TakeawaysAbsci fell 8% today as AI drug discovery peers Schrödinger and Recursion slid in a Nasdaq sell-off. These stocks trade together on sentiment, so the drop says little about Absci’s ...

Webinar will include earnings updates and REC-4881 data as well as KOL and patient panels, presented live from CGA-IGC on Tuesday, November 3, ...

Key TakeawaysAbsci rose 12% today, Schrödinger 11% and Recursion 9%, and no company news explains any of the three moves. Schrödinger’s rally has the most business behind it, and Absci’s rally is ...

Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...

View Recursion Pharmaceuticals, Inc. Class A RXRX stock quote prices, financial information, real-time forecasts, and company news from CNN.

Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...

Monday - Friday, 6:00 - 7:00 PM ET In a Friday interview with CNBC's Jim Cramer, Recursion Pharmaceuticals CEO Chris Gibson discussed how his company is using artificial intelligence and machine ...

Recursion initiates TUPELO, a Phase 2 trial of REC-4881 for the potential treatment of Familial Adenomatous Polyposis (FAP) Recursion initiates a Phase 1 trial for the potential treatment of ...